CAPR
Price
$24.88
Change
+$17.26 (+226.51%)
Updated
Feb 3 closing price
Capitalization
1.36B
49 days until earnings call
Intraday BUY SELL Signals
GNFTY
Price
$7.49
Change
+$3.21 (+75.00%)
Updated
Feb 3 closing price
Capitalization
343.57M
57 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CAPR vs GNFTY

Header iconCAPR vs GNFTY Comparison
Open Charts CAPR vs GNFTYBanner chart's image
Capricor Therapeutics
Price$24.88
Change+$17.26 (+226.51%)
Volume$1.24M
Capitalization1.36B
GENFIT S.A
Price$7.49
Change+$3.21 (+75.00%)
Volume$8.22K
Capitalization343.57M
CAPR vs GNFTY Comparison Chart in %
CAPR
Daily Signal:
Gain/Loss:
GNFTY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CAPR vs. GNFTY commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CAPR is a Hold and GNFTY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (CAPR: $24.88 vs. GNFTY: $7.49)
Brand notoriety: CAPR and GNFTY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CAPR: 40% vs. GNFTY: 296%
Market capitalization -- CAPR: $1.36B vs. GNFTY: $343.57M
CAPR [@Biotechnology] is valued at $1.36B. GNFTY’s [@Biotechnology] market capitalization is $343.57M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CAPR’s FA Score shows that 0 FA rating(s) are green whileGNFTY’s FA Score has 1 green FA rating(s).

  • CAPR’s FA Score: 0 green, 5 red.
  • GNFTY’s FA Score: 1 green, 4 red.
According to our system of comparison, GNFTY is a better buy in the long-term than CAPR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CAPR’s TA Score shows that 5 TA indicator(s) are bullish while GNFTY’s TA Score has 4 bullish TA indicator(s).

  • CAPR’s TA Score: 5 bullish, 3 bearish.
  • GNFTY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CAPR is a better buy in the short-term than GNFTY.

Price Growth

CAPR (@Biotechnology) experienced а +5.78% price change this week, while GNFTY (@Biotechnology) price change was +10.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.22%. For the same industry, the average monthly price growth was +3.03%, and the average quarterly price growth was +35.17%.

Reported Earning Dates

CAPR is expected to report earnings on Mar 25, 2026.

GNFTY is expected to report earnings on Apr 02, 2026.

Industries' Descriptions

@Biotechnology (-4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CAPR($1.36B) has a higher market cap than GNFTY($344M). GNFTY YTD gains are higher at: 21.002 vs. CAPR (-13.791).
CAPRGNFTYCAPR / GNFTY
Capitalization1.36B344M394%
EBITDA-84.92MN/A-
Gain YTD-13.79121.002-66%
P/E RatioN/AN/A-
Revenue11.1MN/A-
Total Cash98.6MN/A-
Total Debt14.5MN/A-
FUNDAMENTALS RATINGS
CAPR vs GNFTY: Fundamental Ratings
CAPR
GNFTY
OUTLOOK RATING
1..100
5687
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
89
Overvalued
PROFIT vs RISK RATING
1..100
4162
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
3537
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CAPR's Valuation (76) in the Biotechnology industry is in the same range as GNFTY (89). This means that CAPR’s stock grew similarly to GNFTY’s over the last 12 months.

CAPR's Profit vs Risk Rating (41) in the Biotechnology industry is in the same range as GNFTY (62). This means that CAPR’s stock grew similarly to GNFTY’s over the last 12 months.

GNFTY's SMR Rating (97) in the Biotechnology industry is in the same range as CAPR (99). This means that GNFTY’s stock grew similarly to CAPR’s over the last 12 months.

CAPR's Price Growth Rating (35) in the Biotechnology industry is in the same range as GNFTY (37). This means that CAPR’s stock grew similarly to GNFTY’s over the last 12 months.

GNFTY's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for CAPR (100). This means that GNFTY’s stock grew significantly faster than CAPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CAPRGNFTY
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
75%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
72%
Declines
ODDS (%)
Bearish Trend 8 days ago
84%
Bearish Trend 7 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CAPR
Daily Signal:
Gain/Loss:
GNFTY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
QSMRX22.410.21
+0.95%
AQR Small Cap Momentum Style R6
RBCIX13.060.04
+0.31%
RBC China Equity I
FDTZX25.58N/A
N/A
Fidelity Advisor Capital Development M
PXINX13.12-0.05
-0.38%
Impax International Sust Econ Inv
ELGAX5.24-0.14
-2.60%
Columbia Select Large Cap Growth A

CAPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, CAPR has been loosely correlated with VRAX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CAPR jumps, then VRAX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAPR
1D Price
Change %
CAPR100%
+7.75%
VRAX - CAPR
48%
Loosely correlated
-1.84%
KRRO - CAPR
33%
Loosely correlated
-2.68%
BEAM - CAPR
33%
Poorly correlated
-0.11%
ACLX - CAPR
32%
Poorly correlated
-0.01%
LXEO - CAPR
32%
Poorly correlated
-1.57%
More

GNFTY and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNFTY has been loosely correlated with SPRB. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if GNFTY jumps, then SPRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNFTY
1D Price
Change %
GNFTY100%
+10.96%
SPRB - GNFTY
39%
Loosely correlated
+7.05%
CVALF - GNFTY
25%
Poorly correlated
+0.82%
ORMP - GNFTY
25%
Poorly correlated
+0.29%
GLTO - GNFTY
25%
Poorly correlated
-6.40%
CAPR - GNFTY
24%
Poorly correlated
+7.75%
More